Silvercrest Asset Management Group LLC Increases Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Silvercrest Asset Management Group LLC lifted its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 39.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 973,888 shares of the medical equipment provider's stock after buying an additional 273,838 shares during the period. Silvercrest Asset Management Group LLC owned approximately 1.40% of Lantheus worth $87,124,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently bought and sold shares of the business. Kestra Investment Management LLC acquired a new position in Lantheus during the fourth quarter worth $27,000. Summit Securities Group LLC purchased a new stake in shares of Lantheus in the 4th quarter valued at approximately $37,000. UMB Bank n.a. raised its position in shares of Lantheus by 31.5% during the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock valued at $50,000 after buying an additional 134 shares during the period. Parkside Financial Bank & Trust lifted its holdings in Lantheus by 49.4% in the fourth quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider's stock valued at $76,000 after acquiring an additional 280 shares during the last quarter. Finally, 1620 Investment Advisors Inc. acquired a new stake in Lantheus during the fourth quarter worth $125,000. Hedge funds and other institutional investors own 99.06% of the company's stock.

Insider Activity

In other Lantheus news, Director Mary Anne Heino sold 53,107 shares of Lantheus stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $94.35, for a total value of $5,010,645.45. Following the transaction, the director now directly owns 440,399 shares in the company, valued at approximately $41,551,645.65. The trade was a 10.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the company's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the sale, the chief financial officer now directly owns 113,860 shares of the company's stock, valued at $11,445,207.20. The trade was a 8.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 63,109 shares of company stock valued at $6,016,046 in the last ninety days. 1.50% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of brokerages recently issued reports on LNTH. B. Riley cut their price objective on Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research report on Friday, March 21st. Truist Financial dropped their price objective on Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. Finally, StockNews.com upgraded shares of Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Seven analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $132.67.

Lantheus Price Performance

NASDAQ:LNTH opened at $79.78 on Friday. The firm has a market capitalization of $5.46 billion, a PE ratio of 13.27 and a beta of 0.23. The business's fifty day moving average price is $97.57 and its 200 day moving average price is $93.51. Lantheus Holdings, Inc. has a 12 month low of $75.00 and a 12 month high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The business had revenue of $372.76 million during the quarter, compared to analyst estimates of $377.37 million. During the same period last year, the company earned $1.69 earnings per share. The business's revenue for the quarter was up .8% compared to the same quarter last year. As a group, equities analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.